Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Danville, VA
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Danville, VA
Click here to add this to my saved trials
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, WV
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, WV
Click here to add this to my saved trials
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marshfield, WI
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated:  12/31/1969
mi
from
Chatswood,
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Status: Enrolling
Updated: 12/31/1969
mi
from
Chatswood,
Click here to add this to my saved trials
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Loma Linda, CA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boulder, CO
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Collins, CO
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
North Haven, CT
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Haven, CT
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Maitland, FL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Naples, FL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Shreveport, LA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Hopedale, MA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Hopedale, MA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chesterfield, MO
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chesterfield, MO
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albany, NY
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amherst, NY
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amherst, NY
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Patchogue, NY
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bellevue, OH
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bellevue, OH
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Medford, OR
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Rumford, RI
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Rumford, RI
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cordova, TN
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cordova, TN
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials